Lomustine
(Synonyms: 洛莫司汀; CCNU; NSC 79037) 目录号 : GC17865
A DNA alkylating agent
Cas No.:13010-47-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Lomustine is an antineoplastic drug used in chemotherapy [1]
Lomustine has been revealed to inhibit the growth of tumour cell lines with IC50 values of 25μM, 8.8μM and 13μM for breast ZR-75-1, astrocytoma U87MG and colorectal LS174T cell lines [2]. Besides, Lomustine has been found to be particularly effective in the treatment of certain neoplasms of the central nervous system, because of the high lipid solubility and permeability through the blood brain barrier. In addition, Lomustine has shown the effect function in treatment of meningeal leukemia in the mouse and in children who have acute leukemia with central nervous system involvement [1].
References:
[1] Cheng CJ, Fujimura S, Grunberger D, Weinstein IB. nteraction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) with nucleic acids and proteins in vivo and in vitro. Cancer Res. 1972 Jan;32(1):22-7.
[2] Baer JC1, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.Br J Cancer. 1993 Jun; 67(6):1299-302.
| Cell experiment [1]: | |
|
Cell lines |
L1210 leukemia cells |
|
Preparation method |
The solubility of this compound in DMSO is >11.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
50 μg/ml, 37°C |
|
Applications |
In L1210 leukemia cells, the radioactivity of the cyclohexyl moiety of CCNU (Lomustine) was bound almost exclusively to proteins, and that of the ethylene group was bound (at a much lower level) to both nucleic acids and proteins. |
| Animal experiment [1]: | |
|
Animal models |
L1210 leukemia-bearing mice |
|
Dosage form |
0.5 mg in 0.2 ml of dimethyl sulfoxide; i.p. injection |
|
Application |
In L1210 leukemia-bearing mice, the radioactivity of the cyclohexyl moiety of CCNU (Lomustine) was almost exclusively bound to cellular proteins, rather than to nucleic acids. The radioactivity of the ethylene moiety was bound to both nucleic acids and proteins of brain, liver, and leukemia cells to about the same level. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Cheng CJ, Fujimura S, Grunberger D, Weinstein IB. Interaction of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037) with nucleic acids and proteins in vivo and in vitro. Cancer Res. 1972 Jan;32(1):22-7. | |
| Cas No. | 13010-47-4 | SDF | |
| 别名 | 洛莫司汀; CCNU; NSC 79037 | ||
| 化学名 | 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea | ||
| Canonical SMILES | C1CCC(CC1)NC(=O)N(CCCl)N=O | ||
| 分子式 | C9H16ClN3O2 | 分子量 | 233.7 |
| 溶解度 | ≥ 11.7mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.279 mL | 21.395 mL | 42.7899 mL |
| 5 mM | 0.8558 mL | 4.279 mL | 8.558 mL |
| 10 mM | 0.4279 mL | 2.1395 mL | 4.279 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet